aXichem AB

Stockholm Stock Exchange AXIC-A.ST

aXichem AB EBITDA for the year ending December 31, 2023: USD -1.49 M

aXichem AB EBITDA is USD -1.49 M for the year ending December 31, 2023, a -25.51% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

aXichem AB EBITDA for the year ending December 31, 2022 was USD -1.19 M, a 20.04% change year over year.
aXichem AB EBITDA for the year ending December 31, 2021 was USD -1.49 M, a -2.03% change year over year.
aXichem AB EBITDA for the year ending December 31, 2020 was USD -1.46 M, a -23.58% change year over year.
aXichem AB EBITDA for the year ending December 31, 2019 was USD -1.18 M, a -20.36% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: AXIC-A.ST

aXichem AB

CEO	Mr. Torsten Helsing
IPO Date	March 4, 2011
Location	Sweden
Headquarters	Södergatan 26
Employees	7
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.

Key trends

Past 5 years